ORIC
Oric Pharmaceuticals, Inc.
$8.85
+0.45%
2026-05-08
About Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Key Fundamentals
Forward P/E
-5.77
EPS (TTM)
$-1.39
ROE
-42.6%
Profit Margin
0.0%
Debt/Equity
1.62
Price/Book
2.27
Beta
1.10
Market Cap
$918.2M
Avg Volume (10D)
1.3M
Recent Breakout Signals
No recent breakout signals detected for ORIC.
Recent Price Range (60 Days)
60D High
$14.25
60D Low
$7.23
Avg Volume
1.9M
Latest Close
$8.85
Get breakout alerts for ORIC
Sign up for Breakout Scanner to receive daily notifications when ORIC triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Oric Pharmaceuticals, Inc. (ORIC) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ORIC daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ORIC operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.